---
title: "Hormone positive disease-adjuvant endocrine treatment"
date: "2023-12-06 14:52:03"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ±ä¾†è‡ª: [[localized breast cancer]]

# Hormone positive disease-adjuvant endocrine treatment

- ER &/or PR positive (IHC > 10%): Always needs endocrine tx. Use of chemo depends on node status & molecular assays
- ER &/or PR low (IHC < 10%): Consider endocrine tx
- Premenopausal: If high risk (age < 35 y +/âˆ’ any high-risk factor, eg, node +) â†’ OFS+TAM or OFS+AI (based on distant relapse & OS â†‘). Note: OFS+AI > OFS + TAM (based on recurrence risk), no OS benefit. (SOFT/TEXT, NEJM 2018;379:122-137; NEJM 2014;371:107-118; JCO 2016;34:1689)
- OFS: Achieve w/ LHRH analogues vs. b/l oophorectomy
- Tox: â†‘ menopausal sxs (Grade 3,4 âˆ¼ 30%) & â†“ bone density
- Low risk: TAM alone, â†“ breast CA mortality (Lancet 1998;351:1451-1467)
- Extended TAM: â†“ breast CA mortality Î” 2.8% vs. 5-y tx, slight â†‘ DVT/PE & endometrial CA (ATLAS, Lancet 2012;381:805; aTTom JCO 2013;13:(suppl; abstr 5))
- TAM tox: DVT, endometrial CA, hot flashes
- Postmenopausal: AI either upfront or sequentially after 5 y of TAM.
- Extended AI (10 y): â†“ Contralateral breast CA, w/ absolute benefit of 4%. No OS benefit. (MA.17R, NEJM 2016;375:209; NSABP-B42, SABC, 2019).
- AI types: (1) Nonsteroidal: Anastrozole, letrozole (2) Steroidal: Exemestane
- AI tox: Arthralgias, â†“ bone density, vaginal dryness
- Additional strategies: Zometa OR denosumab (60 mg q6mos) â†“ skeletal related events & â†‘ DFS for pts on AI, independent of BMD (Lancet 2015;386:433; ABCSG, SABC, 2015)
- CDK4/6 inhibitors + AI currently under investigation (monarchE, PALLAS, NATALEE, PENELOPE B)
- Hormone-positive disease-adjuvant chemotherapy
- Oncotype DX: 21-gene signature RT-PCR assay to calculate Risk Score (RS)-predicts 9-y distant recurrence rate: Low (RS â‰¤11); Intermediate (RS 12-25); High (RS â‰¥26)
- Any pT â‰¥5 mm, pN0, & RS 0-11: ET alone. RS 12-25: ET alone, but consider chemo if <50 & high clinical risk. RS Ãª26: Chemo then ET (TAILORx trial: NEJM 2015;373:2005; NEJM 2018;379:111-121, NEJM 2019;380:2395-2405)
- pN1 (1-3 N+), postmenopausal pt, & RS â‰¤25: ET only (IDFS ET alone âˆ¼ chemo + ET); RS >25: Chemo then ET. If premenopausal, chemo always indicated regardless of RS (RxPONDER, NEJM 2021;385:2336-2347)
- Hormone-positive disease-prognostic models
- MammaPrint: 70-gene signature to categorize into 2 groups-good vs. poor prog irrespective of ER status; if high clinical risk, including 1-3 LN, but good prog on genetic risk, may be able to avoid chemo in postmenopausal pts (MINDACT, Lancet 2005;365:671; updated NEJM 2016;375:717, SABCS 2020)

### Siblings

- [[Local management with surgery and radiation-of-localized breast cancer]]
- [[Chemotherapy regimens for NAV or ADJ use in HR positive and TNBC-of-localized breast cancer]]
- [[Hormone positive disease-adjuvant endocrine treatment]]
- [[Hormone-positive disease-neoadjuvant therapy-of-localized breast cancer]]
- [[HER2-positive disease-of-localized breast cancer]]
- [[Considerations for young patients-of-localized breast cancer]]
